01.02.2018 |
Cai, Sophie; Bressler, Neil M.
Purpose of review
The aim of this study was to provide clinically relevant findings from the DRCR.net Protocol T, a multicentre randomized clinical trial comparing intravitreous aflibercept, repackaged (compounded) bevacizumab and ranibizumab for vision-impairing centre-involved diabetic macular oedema (DME).
Current Opinion in Ophthalmology 28(6):p 636-643, November 2017. | DOI: 10.1097/ICU.0000000000000424